Facebook-square Twitter Youtube

Can ICER Put a Price on Asthma Control?

The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details.

View the Graphic.

View Social Graphics.

Tagged

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to our newsletter
© 2023, Alliance for Patient Access.
Website Management provided by Genacom
2020 K Street NW, Suite 505 Washington, DC 20006
[email protected]
(202) 951-7097
Facebook-square Twitter Youtube